ArticleMovement disorders : official journal of the Movement Disorder Society2016
Arguing against the proposed definition changes of PD.
Article in Movement disorders : official journal of the Movement Disorder Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies.Molecular neurodegeneration · 2025Review
- Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- A Call for Change: Updating the Operational Definition for Dementia in Parkinson's Disease.Movement disorders clinical practice · 2025Article
- Clinicopathological Heterogeneity of Lewy Body Diseases: The Profound Influence of Comorbid Alzheimer's Disease.medRxiv : the preprint server for health sciences · 2024Article
- [Dementia with Lewy bodies: old and new knowledge - Part 1: clinical aspects and diagnostics].Der Nervenarzt · 2024Review
- Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Same, same … but different!Brain : a journal of neurology · 2023Article
- Advancing the Genetics of Lewy Body Disorders with Disease-Modifying Treatments in Mind.Advanced genetics (Hoboken, N.J.) · 2022Article
- Lewy Body Dementias: Controversies and Drug Development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Parkinson disease-associated cognitive impairment.Nature reviews. Disease primers · 2021Review
- Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.Neurology · 2021Article
- Advances in dementia with Lewy bodies.Therapeutic advances in neurological disorders · 2021Review
- Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies.Journal of neurology · 2020Article
- Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy.International journal of molecular sciences · 2020Review
- Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.Movement disorders : official journal of the Movement Disorder Society · 2020Review
- Clinical drug development for dementia with Lewy bodies: past and present.Expert opinion on investigational drugs · 2019Review
- Differential insular cortex subregional vulnerability to α-synuclein pathology in Parkinson's disease and dementia with Lewy bodies.Neuropathology and applied neurobiology · 2019Article
- Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.Annals of neurology · 2019Article
- Dementia with Lewy bodies: an update and outlook.Molecular neurodegeneration · 2019Review
Corrections and comments
- Comment on
Authors and funding
20 authors.
Funding
Abstract
As members of the Lewy Body Dementia Association Scientific Advisory Council, we aim to address some of the issues raised in the article titled "Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease." In particular, we suggest that the 1-year rule distinguishing Parkinson's disease dementia from dementia with Lewy bodies is worth maintaining because it serves an important purpose in clinical practice and clinical and basic science research and when helping the lay community understand the complexity of these different clinical phenotypes. Furthermore, we believe that adding an additional diagnostic label, "PD (dementia with Lewy bodies subtype)," will confuse rather than clarify the distinction between dementia with Lewy bodies and PD or PD dementia, and will not improve management or expedite therapeutic development. We present arguments supporting our contentions. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.